OXFORD, UK – 8 July 2014 - Glide Pharma, the pharmaceutical development and device company focused on solid dose formulations of therapeutics and vaccines, today announced the appointment of Richard Bungay as Chief Financial Officer and Tony Mills as Director of Business Development. Both Mr Bungay and Dr Mills have extensive experience of the life sciences industry, and bring significant senior level corporate and commercial expertise to Glide.
Richard Bungay has over 20 years’ corporate experience of the biotechnology and pharmaceutical sectors. His recent roles include CFO at Verona Pharma Plc and CEO of Chroma Therapeutics, prior to which he was Chroma’s CFO. Previously, he was Director of Corporate Communications and Strategic Planning at Celltech, following a period as Finance Director for AstraZeneca’s Respiratory and Inflammation Therapy Area. He also held a number of finance positions at Celltech, including Financial Controller. He qualified as a Chartered Accountant at Deloitte.
Tony Mills brings over 25 years’ commercial experience of the life sciences industry to Glide. He joins the company from the drug delivery company Q Chip Ltd where he was Chief Commercial Officer. He was also Vice President, Business Development at BioVex Ltd, and held several roles at BTG International including Vice President, Genomics and Proteomics. He holds a PhD in Virology from Liverpool University.
Commenting on the appointments, Dr Mark Carnegie-Brown, Glide Pharma’s CEO, said, “I’m delighted to welcome Richard and Tony to the Glide team. Both are seasoned industry professionals, and attracting executives of their calibre is a testament to the progress Glide has made since completing a strategic fundraising last year for the scale-up of our device and formulation capabilities.”
Commenting on his appointment, Richard Bungay, Glide Pharma’s CFO, said, “Glide has entered an exciting period as its novel technology moves towards commercial scale-up, and I look forward to working with the team as the company enters its next stage of corporate development.”
Commenting on his appointment, Tony Mills, Glide Pharma’s Director of Business Development, said, “I am impressed with the recent progress Glide has made with its delivery technology, and look forward to helping the company exploit the new commercial opportunities this opens up across the industry.”
About Glide Pharma
Glide Pharma is a pharmaceutical development and device company focused on solid dose formulations of therapeutics and vaccines. The company’s products are based on its proprietary solid dose injector, the Glide SDI®, which offers the potential of improved compliance in long-term therapy and enhanced immune responses to vaccines. Glide’s pipeline includes octreotide, parathyroid hormone and anthrax and influenza vaccines.
The company has a strong management team with extensive experience of the pharmaceutical, biotechnology and medical device sectors. Glide Pharma has successfully completed five investment rounds, and is supported by a consortium of institutional and private technology investors, including Invesco Perpetual, Oxford Technology Venture Capital Trusts, Oxford Capital Partners and Hygea VCT. For more information please visit www.glidepharma.com.
Contacts
Dr Mark Carnegie-Brown
Chief Executive
Glide Pharma
Tel: +44 (0)1235 577120
Rob Budge
RJB Communications
Tel: +44 (0)1865 760969
Mobile: +44 (0)7710 741241
Help employers find you! Check out all the jobs and post your resume.
